NAMS — NewAmsterdam Pharma Share News
0.000.00%
Last trade - 00:00- $2.46bn
- $1.83bn
- $22.50m
Brief: Newamsterdam Pharma Announces Pricing Of $175.3 Mln Public Offering Of Ordinary Shares And Pre-Funded Warrants
Brief: NewAmsterdam Appoints William H. Lewis as Chair of its Board of Directors
Brief: Newamsterdam Pharma Announces 2024 Strategic Priorities
Brief: Newamsterdam Pharma Announces Appointment Of Ian Somaiya As Chief Financial Officer
Brief: NewAmsterdam Pharma Completes Enrollment In Late-Stage Study Of Heart Disease Treatment
Brief: Newamsterdam Pharma Announces Pricing Of Upsized Secondary Offering Of Ordinary Shares
Brief: NewAmsterdam Pharma Announces Commencement Of Secondary Offering Of Shares
Brief: NewAmsterdam Pharma Announces Positive Topline Results From Phase 2B Obicetrapib Trial In Japanese Patients
Brief: Newamsterdam Pharma Says Full Data From Phase 2 Rose2 Trial Evaluating Obicetrapib In Combination With Ezetimibe As An Adjunct To High-Intensity Statin Therapy
Brief: Newamsterdam Pharma Completes Enrollment In Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia
Brief: Newamsterdam Pharma Reports Full Year 2022 Financial Results And Provides Corporate Update
NewAmsterdam Pharma rises on positive data in cholesterol-lowering treatment trial
Brief: NewAmsterdam Announces Positive Results From ROSE2, Phase 2 Trial
Brief: NewAmsterdam Pharma Files For Offering Of Up To 77.1 Mln Shares
Brief: Newamsterdam Pharma Company NV Announces Appointment Of David Topper As Chief Financial Officer
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Blackstone, Ford
U.S. STOCKS ON THE MOVE-Manchester United, Tesla, Deere
Media: Frazier SPAC Is in Talks to Merge With NewAmsterdam Pharma - Bloomberg News